Norbert Schmitz

Q: What Schools Are Affiliated With Norbert Schmitz

Norbert Schmitz is affiliated with the following schools: University of Jena, Leipzig University, University of Southampton, Saarland University, Washington University in St. Louis, University of Cologne, Charles University, Kiel University

Norbert Schmitz's AcademicInfluence.com Rankings

Norbert Schmitz

Computer Science

#7150

World Rank

#7530

Historical Rank

Machine Learning

#2553

World Rank

#2587

Historical Rank

Artificial Intelligence

#2840

World Rank

#2884

Historical Rank

Database

#4209

World Rank

#4377

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Why Is Norbert Schmitz Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Norbert Schmitz's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of t (2005) (1280)
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. (2010) (1235)
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. (2013) (1143)
Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial (2002) (1003)
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). (2008) (987)
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. (2004) (716)
Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients (1996) (636)
Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). (2000) (537)
Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. (2010) (524)
Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor) (1995) (513)
MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. (2013) (487)
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. (2004) (482)
Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. (2010) (461)
Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. (2002) (398)
Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. (2009) (360)
G‐CSF‐mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft (1994) (324)
An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation (2003) (316)
Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. (2008) (311)
Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. (2004) (303)
Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. (2010) (300)
CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). (2009) (281)
ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. (2013) (280)
Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe (2002) (275)
Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe in 1998 (1998) (272)
Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. (2017) (265)
The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. (2011) (263)
CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. (2016) (262)
Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation (1998) (259)
Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. (2002) (256)
A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. (2016) (252)
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group (2017) (243)
Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). (2006) (237)
Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. (2012) (235)
Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. (1995) (234)
Early recurrence or persistence of autoimmune diseases after unmanipulated autologous stem cell transplantation. (1996) (217)
Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). (2012) (211)
Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study (2016) (208)
ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome (2013) (197)
Allogeneic blood stem cell transplantation: considerations for donors. (1997) (192)
Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. (2002) (190)
Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. (2014) (189)
Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. (2010) (189)
Severe events in donors after allogeneic hematopoietic stem cell donation (2009) (186)
International Consensus Conference on high-dose therapy with hematopoietic stem-cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. (1999) (180)
Autologous haematopoietic stem cell transplants for autoimmune disease – feasibility and transplant-related mortality (1999) (180)
Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. (2008) (177)
Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group. (2017) (175)
Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. (2004) (173)
Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries (2003) (168)
Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. (2010) (166)
Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin’s lymphoma: identification of prognostic factors predicting outcome (2009) (165)
International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury. (1999) (164)
Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT (1999) (162)
Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. (2009) (160)
Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma. (1997) (158)
Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. (2003) (157)
Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma (2007) (154)
Long-term outcome of patients given transplants of mobilized blood or bone marrow: A report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. (2006) (154)
Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. (2015) (153)
The effects of rituximab treatment during pregnancy on a neonate. (2006) (151)
Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. (2010) (151)
High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. (2018) (149)
High-Dose Therapy and Autologous Stem-Cell Transplantation for Adult Patients With Hodgkin's Disease Who Do Not Enter Remission After Induction Chemotherapy: Results in 175 Patients Reported to the European Group for Blood and Marrow Transplantation (1999) (147)
Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma. (2002) (143)
Development of leukemia in donor cells after allogeneic stem cell transplantation--a survey of the European Group for Blood and Marrow Transplantation (EBMT). (2005) (134)
Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study (2007) (134)
Peripheral blood stem cell donation: an analysis from the International Bone Marrow Transplant Registry (IBMTR) and European Group for Blood and Marrow Transplant (EBMT) databases (2001) (132)
High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry. (2001) (130)
Allogeneic granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for treatment of engraftment failure after bone marrow transplantation [letter] (1993) (129)
Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation. (2009) (126)
Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium. (2019) (123)
CNS Disease In Younger Patients ( (2010) (120)
Generation of Cytotoxic Responses in Mice and Human Individuals Against Hematological Malignancies Using Survivin-RNA-Transfected Dendritic Cells1 (2003) (118)
Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group. (1994) (116)
High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. (2010) (115)
Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma (2008) (114)
The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status. (2004) (113)
Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial. (2010) (113)
Suboptimal dosing of rituximab in male and female patients with DLBCL. (2014) (113)
Hematopoietic stem cell transplantation for hematological malignancies in Europe (2003) (112)
Impaired binding of perforin on the surface of tumor cells is a cause of target cell resistance against cytotoxic effector cells. (2000) (110)
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial (2019) (109)
High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingd (2001) (107)
Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation. (2013) (107)
TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial. (2013) (102)
Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study (2017) (102)
International prognostic indices in diffuse large B-cell lymphoma (DLBCL): a comparison of IPI, R-IPI and NCCN-IPI. (2020) (98)
High-Dose Therapy and Autologous Stem-Cell Transplantation in Angioimmunoblastic Lymphoma: Complete Remission at Transplantation Is the Major Determinant of Outcome—Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (2008) (98)
Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma. (2016) (96)
Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. (2014) (95)
Transplantation of peripheral blood progenitor cells from HLA‐identical sibling donors (1996) (94)
CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. (2012) (94)
Cytarabine dose of 36 g/m² compared with 12 g/m² within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study. (2011) (91)
Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial (2008) (90)
Differences between graft product and donor side effects following bone marrow or stem cell donation (2003) (88)
Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement. (2013) (87)
Effective mobilisation of peripheral blood progenitor cells with 'Dexa-BEAM' and G-CSF: timing of harvesting and composition of the leukapheresis product. (1993) (85)
THE PLACE OF BLOOD STEM CELLS IN ALLOGENEIC TRANSPLANTATION (1996) (85)
The International Prognostic Index determines the outcome of patients with nodal mature T‐cell lymphomas (2005) (83)
Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies. (2003) (82)
G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: comparison of T cell depletion strategies using different CD34+ selection systems or CAMPATH-1. (1995) (82)
Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group. (2014) (79)
Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD. (2016) (74)
Allogeneic stem-cell transplantation in patients with Waldenström macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. (2010) (73)
Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation. (2009) (72)
Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a European society for blood and marrow transplantation lymphoma working party extended analysis. (2014) (71)
Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe (2002) (70)
Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group. (1998) (67)
Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial. (2015) (67)
Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial. (2005) (67)
Early stem cell transplantation for chronic lymphocytic leukaemia: a chance for cure? (1998) (66)
High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). (2009) (66)
High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial. (2013) (66)
Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma. (2006) (66)
Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome. (2007) (65)
Optimizing engraftment--source and dose of stem cells. (2002) (65)
Induction of antitumour immunity using survivin peptide‐pulsed dendritic cells in a murine lymphoma model (2003) (64)
Six, Not Eight Cycles of Bi-Weekly CHOP with Rituximab (R-CHOP-14) Is the Preferred Treatment for Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). (2005) (64)
A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin’s lymphoma receiving chemotherapy (2008) (63)
Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma (2015) (62)
Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. (1995) (61)
Allogeneic granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for treatment of engraftment failure after bone marrow transplantation. (1993) (61)
High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party. (1999) (60)
TP53 mutation and survival in aggressive B cell lymphoma (2017) (60)
Is there a graft‐versus‐leukaemia effect in the absence of graft‐versus‐host disease in patients undergoing bone marrow transplantation for acute leukaemia? (2000) (59)
ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma (2018) (59)
Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up. (2009) (58)
Allogeneic peripheral blood progenitor cell transplantation in a murine model : Evidence for an improved graft-versus-leukemia effect (1997) (57)
Significance of cytogenetic findings for the clinical outcome in patients with T-cell lymphoma of angioimmunoblastic lymphadenopathy type. (1996) (57)
Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders. Current practice in Europe in 1996 and proposals for an operational classification. Accreditation Sub-Committee of the European Group for Blood and Marrow Transplantation (EBMT). (1996) (56)
Monitoring of chimerism after allogeneic bone marrow transplantation with unmanipulated marrow by use of DNA polymorphisms. (1993) (56)
Allogeneic MHC‐mismatched activated natural killer cells administered after bone marrow transplantation provide a strong graft‐versus‐leukaemia effect in mice (1997) (56)
Myeloablative radiochemotherapy followed by autologous peripheral blood stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: first results of a prospective multicenter study. (2004) (55)
Autologous Stem Cell Transplantation for Patients with Early Progression of Follicular Lymphoma: A Follow-Up Study of 2 Randomized Trials from the German Low Grade Lymphoma Study Group. (2018) (55)
Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma (2018) (55)
Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial. (2017) (55)
Allogeneic transplantation in lymphoma: current status (2007) (54)
Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL). (2018) (54)
Allogeneic and autologous stem cell transplantation for hepatosplenic T-cell lymphoma: a retrospective study of the EBMT Lymphoma Working Party (2014) (54)
Autologous stem cell transplantation in lymphoma. (2007) (52)
First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation (2016) (50)
Six versus eight cycles of biweekly CHOP-14 with or without R in elderly patients (pts) with aggressive CD20+ B-cell lymphomas: Seven-year FU of the RICOVER-60 trial of the DSHNHL. (2011) (50)
High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. (2008) (50)
Combined positive/negative selection for highly effective purging of PBPC grafts: towards clinical application in patients with B-CLL (1997) (50)
Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia : long-term clinical and MRD results of the German CLL Study Group CLL 3 X trial (2010) (49)
Sorafenib In Combination with Standard Induction and Consolidation Therapy In Elderly AML Patients: Results From a Randomized, Placebo-Controlled Phase II Trial (2010) (48)
Velcade, Intravenous Cyclophosphamide and Dexamethasone (VCD) Induction for Previously Untreated Multiple Myeloma (German DSMM XIa Trial). (2009) (48)
Myeloablative radiochemotherapy followed by reinfusion of purged autologous stem cells for Waldenström's macroglobulinaemia (1999) (48)
R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study. (2009) (47)
Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the study alliance leukemia (2016) (47)
Fractionated total body irradiation and high-dose VP 16-213 followed by allogeneic bone marrow transplantation in advanced leukemias (1988) (47)
How I manage peripheral T‐cell lymphoma, not otherwise specified and angioimmunoblastic T‐cell lymphoma: current practice and a glimpse into the future (2017) (47)
Fatal course of an autochthonous hepatitis E virus infection in a patient with leukemia in Germany (2012) (47)
Allogeneic hematopoietic stem cell transplantation for T-cell lymphomas. (2018) (46)
Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). (2008) (46)
Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials (2018) (46)
Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia (2016) (46)
Autografting of highly purified peripheral blood progenitor cells following myeloablative therapy in patients with lymphoma: a prospective study of the long-term effects on tumor eradication, reconstitution of hematopoiesis and immune recovery (1999) (46)
Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment (2015) (45)
The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients. (2000) (44)
Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma – analyses of cases from two prospective randomized clinical trials (2009) (43)
Patterns and outcome of relapse after autologous stem cell transplantation for mantle cell lymphoma (2011) (42)
Lenograstim after autologous peripheral blood progenitor cell transplantation: results of a double-blind, randomized trial (2004) (42)
Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM) (2003) (41)
Treatment of relapsed or refractory adult acute lymphocytic leukemia (1992) (41)
The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas. (2014) (41)
Nilotinib (Tasigna®) and chemotherapy for first-line treatment in elderly patients with De Novo Philadelphia chromosome/BCR-ABL1 positive acute Lymphoblastic Leukemia (ALL): A trial of the European Working Group for Adult ALL (EWALL-PH-02) (2014) (41)
Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia. (2011) (40)
Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial (2020) (39)
Stem-cell transplantation for chronic lymphocytic leukemia: the 1999 perspective. (2000) (39)
Allogeneic peripheral blood progenitor cells for treatment of relapse after bone marrow transplantation (1997) (39)
Staging systems for multiple myeloma: a comparison (1985) (39)
Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high-dose therapy as in vivo purging and to maintain remission following high-dose therapy. (2010) (38)
High lytic activity against human leukemia cells after activation of allogeneic NK cells by IL-12 and IL-2. (1996) (38)
Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial (2019) (38)
Identification of HLA-A*0201-Presented T Cell Epitopes Derived from the Oncofetal Antigen-Immature Laminin Receptor Protein in Patients with Hematological Malignancies (2006) (37)
German consensus on immunogenetic donor search for transplantation of allogeneic bone marrow and peripheral blood stem cells (1997) (36)
Conservative Management of Gastric Lymphoma: the Treatment Option of Choice (2004) (36)
Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients (2017) (36)
The prognostic impact of minimal residual disease assessment after stem cell transplantation for chronic lymphocytic leukemia: is achievement of molecular remission worthwhile? (2005) (36)
Recurrence of acute lymphoblastic leukemia in donor cells after allogeneic marrow transplantation associated with a deletion of the long arm of chromosome 6. (1987) (34)
Six vs. Eight Cycles of Bi-Weekly CHOP-14 with or without Rituximab for Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of the Completed RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). (2006) (34)
ATRA and Arsenic Trioxide (ATO) Versus ATRA and Idarubicin (AIDA) for Newly Diagnosed, Non High-Risk Acute Promyelocytic Leukemia (APL): Results of the Phase III, Prospective, Randomized, Intergroup APL0406 Study by the Italian-German Cooperative Groups Gimema-SAL-AMLSG (2012) (34)
PBSC collection from family donors in Japan: a prospective survey (2014) (34)
Randomized Comparison of Interferon-a With Busulfan and Hydroxyurea in Chronic Myelogenous Leukemia (2002) (34)
Dose-dense chemotherapy in breast cancer and lymphoma. (2004) (34)
High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma. (2010) (34)
Intensive chemotherapy and bone marrow transplantation for myelodysplastic syndromes. (1992) (33)
Allogeneic or autologous transplantation as first-line therapy for younger patients with peripheral T-cell lymphoma: Results of the interim analysis of the AATT trial. (2017) (33)
Relapse in common lymphoma subtypes: salvage treatment options for follicular lymphoma, diffuse large cell lymphoma and Hodgkin disease (2006) (33)
Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial (2014) (32)
Reduced-intensity conditioning prior to allogeneic transplantation of hematopoietic stem cells: the need for T cells early after transplantation to induce a graft-versus-lymphoma effect (2004) (32)
Risk stratification using a new prognostic score for patients with secondary acute myeloid leukemia: results of the prospective AML96 trial (2011) (32)
Allogeneic transplantation of hematopoietic stem cells after nonmyeloablative conditioning for Hodgkin's disease: indications and results. (2004) (31)
Reply to K. Tay et al (2011) (31)
Sequential high-dose therapy and autologous stem cell transplantation for treatment of mantle cell lymphoma. (1997) (30)
Second German consensus on immunogenetic donor search for allotransplantation of hematopoietic stem cells (2001) (30)
High-dose therapy and autologous stem cell transplantation for extra-nodal NK/T lymphoma in patients from the Western hemisphere: a study from the European Society for Blood and Marrow Transplantation (2015) (30)
Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL) after dose-dense rituximab: Results of the DENSE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) (2008) (30)
Purging Peripheral Blood Progenitor Cell Grafts from Lymphoma Cells: Quantitative Comparison of Immunomagnetic CD34+ Selection Systems (1997) (30)
A prospective study of positive/negative ex vivo B-cell depletion in patients with chronic lymphocytic leukemia. (2000) (30)
Validation of a Prognostic Model to Assess the Risk of CNS Disease in Patients with Aggressive B-Cell Lymphoma (2014) (29)
Cytogenetic studies on recipients of allogeneic bone marrow transplants after fractionated total body irradiation (1985) (29)
Fractionated total body irradiation and high-dose VP 16-213 followed by allogeneic bone marrow transplantation in advanced leukemias. (1988) (29)
Is there a graft-versus-leukaemia effect in the absence of graft-versus-host disease in patients undergoing bone marrow transplantation for acute leukaemia? (2000) (29)
Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin's lymphoma: results of a phase II study. (2006) (29)
Aggressive Chemotherapy (CHOEP-14) and Rituximab or High-Dose Therapy (MegaCHOEP) and Rituximab for Young, High-Risk Patients with Aggressive B-Cell Lymphoma: Results of the MegaCHOEP Trial of the German High — Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). (2009) (28)
Comparison of different strategies of molecular genetic monitoring following autologous stem cell transplantation in patients with follicular lymphoma (1998) (28)
CHO(E)P-14 followed by alemtuzumab consolidation in untreated peripheral T cell lymphomas: final analysis of a prospective phase II trial (2013) (28)
ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients (2019) (28)
Radiotherapy (RT) to bulky (B) and extralymphatic (E) disease in combination with 6xR-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: Results of the 2x2 randomized UNFOLDER trial of the DSHNHL/GLA. (2018) (28)
Role of allogeneic stem cell transplantation in relapsed or refractory Hodgkin's disease. (2002) (27)
Comparison of cyclophosphamide, cytarabine, and etoposide as immunosuppressive agents before allogeneic bone marrow transplantation. (1988) (27)
Conventional chemoimmunotherapy (R-CHOEP-14) or high-dose therapy (R-Mega-CHOEP) for young, high-risk patients with aggressive B-cell lymphoma: Final results of the randomized Mega-CHOEP trial of the German High-Grade Non-Hodgkin Lymphona Study Group (DSHNHL). (2011) (27)
Rapid engraftment of peripheral blood progenitor cell grafts purged with B cell-specific monoclonal antibodies and immunomagnetic beads. (1995) (26)
Haematopoietic SCT for children and adolescents with relapsed and refractory Hodgkin's lymphoma (2008) (26)
Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial. (2012) (25)
Use of intrathecal prophylaxis in allogeneic haematopoietic stem cell transplantation for malignant blood diseases: a survey of the European Group for Blood and Marrow Transplantation (EBMT) (2005) (25)
Identification of a survivin-derived peptide that induces HLA-A*0201-restricted antileukemia cytotoxic T lymphocytes (2004) (25)
Therapeutic effects of idiotype vaccination can be enhanced by the combination of granulocyte–macrophage colony‐stimulating factor and interleukin 2 in a myeloma model (2003) (25)
High-risk additional chromosomal abnormalities at low blast counts herald death by CML (2020) (25)
Survivin-derived peptide epitopes and their role for induction of antitumor immunity in hematological malignancies (2006) (25)
PEG-Asparaginase in Adult Acute Lymphoblastic Leukemia (ALL): Efficacy and Feasibility Analysis with Increasing Dose Levels (2008) (24)
A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL (2019) (24)
Developments in allogeneic peripheral blood progenitor cell transplantation. (1998) (24)
Autologous stem cell transplantation for follicular lymphoma: no benefit for early transplant? (2001) (24)
Reduced-intensity allogeneic stem cell transplantation as salvage treatment for patients with indolent lymphoma or CLL after failure of autologous SCT (2000) (23)
R-ICE Versus R-DHAP in Relapsed Patients with CD20 Diffuse Large B-Cell Lymphoma (DLBCL) Followed by Stem Cell Transplantation and Maintenance Treatment with Rituximab or Not: First Interim Analysis on 200 Patients. CORAL Study. (2007) (23)
Allogeneic peripheral blood stem cell transplantation following fludarabine-based conditioning in six children with advanced Hodgkin’s disease (2004) (23)
Maintenance with rituximab after autologous stem cell transplantation in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL): CORAL final analysis. (2011) (22)
Autologous stem cell transplantation as part of first-line treatment of Waldenström's macroglobulinemia. (2007) (22)
ZUMA-7: A phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) versus standard-of-care (SOC) therapy in patients with relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL). (2018) (21)
Allogeneic peripheral blood progenitor cell transplantation in a murine model: evidence for an improved graft-versus-leukemia effect. (1997) (21)
Impact of allogeneic haematopoietic stem cell transplantation in patients with abnl(17p) acute myeloid leukaemia (2013) (21)
Standards for blood and marrow progenitor cell processing, collection and transplantation (2000) (21)
Increased rituximab (R) doses and effect on risk of elderly male patients with aggressive CD20+ B-cell lymphomas: Results from the SEXIE-R-CHOP-14 trial of the DSHNHL. (2014) (21)
CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. (2012) (21)
Higher than expected transplant-related mortality and relapse following nonmyeloablative stem cell transplantation for lymphoma adversely effects progression free survival. (2000) (20)
Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation in myeloid diseases (2003) (20)
Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). The German CML Study Group. (1996) (20)
Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: Results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL>60 study of the DSHNHL. (2017) (20)
Advances in the Treatment of Secondary CNS Lymphoma. (2015) (20)
Carmustine and the lungs (1997) (20)
Advanced patient age at diagnosis of diffuse large B-cell lymphoma is associated with molecular characteristics including ABC-subtype and high expression of MYC (2018) (20)
A NEW PROGNOSTIC MODEL TO ASSESS THE RISK OF CNS DISEASE IN PATIENTS WITH AGGRESSIVE B-CELL LYMPHOMA (2013) (20)
Alemtuzumab added to CHOP for treatment of peripheral T-cell lymphoma (pTNHL) of the elderly: Final results of 116 patients treated in the international ACT-2 phase III trial. (2016) (20)
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients (2018) (19)
Haploidentical ‘megadose’ stem cell transplantation in acute leukemia: recommendations for a protocol agreed upon at the Perugia and Chicago meetings (2002) (19)
A Phase III Study Of Enzastaurin In Patients With High-Risk Diffuse Large B Cell Lymphoma Following Response To Primary Treatment: The Prelude Trial (2013) (19)
Graft-vs-leukemia activity and graft-vs-host disease induced by allogeneic Th1- and Th2-type CD4+ T cells in mice. (2001) (19)
Splenic irradiation before bone marrow transplantation for chronic myeloid leukaemia (1996) (18)
Rituximab in Combination with CHOP in Patients with Follicular Lymphoma: Analysis of Treatment Outcome of 552 Patients Treated in a Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG) after a Follow up of 58 Months (2008) (18)
Reduced Intensity Allogeneic Stem Cell Transplantation for Hodgkin’s Disease. Outcome Depends Primarily on Disease Status at the Time of Transplantation. (2004) (18)
Allogeneic transplantation in T-cell lymphomas. (2014) (18)
A randomized phase 3 trial of auto vs. allo transplantation as part of first-line therapy in poor-risk peripheral T-NHL. (2020) (18)
High-dose chemotherapy and autologous bone marrow transplantation in relapsing angioimmunoblastic lymphadenopathy with dysproteinemia (AILD). (1991) (18)
The Role of Radiotherapy to Bulky Disease in the Rituximab Era: Results from Two Prospective Trials of the German High-Grade Non-Hodgkin- Lymphoma Study Group (DSHNHL) for Elderly Patients with DLBCL (2008) (18)
Recombinant Human Granulocyte-Macrophage Colony-stimulating Factor After Autologous Bone Marrow Transplantation (1990) (18)
Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia (CLL) with 17p Deletion: A Retrospective EBMT Analysis. (2007) (17)
HYPOMAGNESAEMIA AND CYCLOSPORIN TOXICITY (1985) (17)
Male Sex Is Associated with Lower Rituximab Trough Serum Levels and Evolves as a Significant Prognostic Factor in Elderly Patients with DLBCL Treated with R-CHOP: Results From 4 Prospective Trials of the German High-Grade Non-Hodgkin-Lymphoma Study Group (DSHNHL). (2009) (17)
Rituximab for Graft-Versus-Host-Disease-Prophylaxis after Allogeneic Stem Cell Transplantation Given as Treatment of High Risk Relapse of Aggressive Lymphoma: Results of a Randomized Phase II Study. (2008) (17)
Dose escalation of cytotoxic drugs using haematopoietic growth factors: a randomized trial to determine the magnitude of increase provided by GM-CSF. (2001) (17)
Transplantation of allogeneic peripheral blood progenitor cells--the EBMT experience. (1996) (16)
Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA mutations (2017) (16)
Allogeneic peripheral blood progenitor cells: current status and future directions. (1996) (16)
Eradication of residual disease by administration of leukemia-specific T cells after experimental allogeneic bone marrow transplantation. (1998) (16)
Is there a rationale for high-dose chemotherapy as first line treatment of advanced Hodgkin's disease? German Hodgkin's Lymphoma Study Group (GHSG). (1995) (15)
Allogenic transplantation of mobilized peripheral blood progenitor cells: towards tailored cell therapy. (1997) (15)
Intensive chemotherapy and bone marrow transplantation for myelodysplastic syndromes. (1992) (15)
Humoral Immune Responses against the Immature Laminin Receptor Protein Show Prognostic Significance in Patients with Chronic Lymphocytic Leukemia12 (2008) (15)
Evaluation of the proposed reporting system of the European LeukemiaNet and recommendations for prognosis of acute myeloid leukemia. (2013) (14)
Allogeneic transplantation of peripheral blood progenitor cells. (1995) (14)
Dose-Dense Rituximab Improves Outcome of Elderly Patients with Poor-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL): Results of the DENSE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). (2007) (14)
Peripheral Blood Hematopoietic Cells for Allogeneic Transplantation (2007) (14)
Hematopoietic stem cell transplantation in patients with lymphomatoid granulomatosis: a European group for blood and marrow transplantation report. (2013) (14)
Excellent Outcome of Young Patients (18-60 years) with Favourable-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 4 Cycles CHOP Plus 6 Applications of Rituximab: Results of the 592 Patients of the Flyer Trial of the Dshnhl/GLA (2018) (14)
Investigating the lysis of small-cell lung cancer cell lines by activated natural killer (NK) cells with a fluorometric assay for NK-cell-mediated cytotoxicity (1999) (14)
Identification of Prognostic Factors Predicting the Outcome of Reduced Intensity Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma. An Analysis from the Lymphoma Working Party of the EBMT (2008) (14)
Prognostic Factors for Outcome of Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) in Poor-Risk Chronic Lymphocytic Leukemia (CLL): Final Results from a Prospective Multicenter Trial (GCLLSG CLL3X study) (2008) (13)
Standards for specialist units undertaking blood and marrow stem cell transplants--recommendations from the EBMT. Accreditation Sub-Committee of the European Group for Blood and Marrow Transplantation (EBMT). (1995) (13)
Treatment results of aggressive B non‐Hodgkin's lymphoma in advanced age considering comorbidity (2002) (13)
ESMO Consensus Conference on malignant lymphoma: management of ‘ultra-high-risk’ patients (2018) (13)
A 70% cut-off for MYC protein expression in diffuse large B cell lymphoma identifies a high-risk group of patients. (2020) (13)
The role of stem cell transplantation in the treatment of chronic lymphocytic leukemia. (1997) (13)
Idiotype protein-pulsed dendritic cells produce strong anti-myeloma effects after syngeneic stem cell transplantation in mice (2002) (13)
The impact of SOCS1 mutations in diffuse large B‐cell lymphoma (2019) (13)
A prospective multicenter trial with human recombinant alpha 2c-interferon in hairy cell leukemia before and after splenectomy. (1987) (13)
Allogeneic stem cell transplantation for patients with relapsed or refractory T-cell lymphoma: efficacy of lymphoma-directed conditioning against advanced disease (2018) (13)
RADIOTHERAPY TO BULKY DISEASE PET‐NEGATIVE AFTER IMMUNOCHEMOTHERAPY CAN BE SPARED IN ELDERLY DLBCL PATIENTS: RESULTS OF a PLANNED INTERIM ANALYSIS OF THE FIRST 187 PATIENTS WITH BULKY DISEASE TREATED IN THE OPTIMAL > 60 STUDY OF THE DSHNHL (2017) (12)
Allogeneic stem cell transplantation after reduced-intensity conditioning in lymphoid malignancies (2003) (12)
Morphological and cytochemical classification of adult acute leukemias in two multicenter studies in the Federal Republic of Germany. (1987) (12)
Improved Outcome with ATRA-Arsenic Trioxide Compared to ATRA-Chemotherapy in Non-High Risk Acute Promyelocytic Leukemia – Updated Results of the Italian-German APL0406 Trial on the Extended Final Series (2014) (12)
Granulocyte‐colony‐stimulating factor induces increased serum levels of soluble interleukin 2 receptors preceding engraftment in autologous bone marrow transplantation (1993) (12)
Molecular subtypes of NPM 1 mutations have different clinical profiles , specific patterns of accompanying molecular mutations and varying outcome in intermediate risk acute myeloid leukemia (2015) (12)
Actual role and perspectives of BMT in children. (1989) (12)
Cutaneous gamma/delta T‐cell lymphoma (2009) (12)
The best treatment for diffuse large B-cell lymphoma: a German perspective. (2005) (12)
The Role of Allogeneic Stem Cell Transplantation in Hodgkin’s Lymphoma (2014) (11)
Gamma-irradiation of blood products following autologous stem cell transplantation: surveillance of the policy of 35 centers (2003) (11)
Role of radiotherapy and dose-densification of R-CHOP in primary mediastinal B-cell lymphoma: A subgroup analysis of the unfolder trial of the German Lymphoma Alliance (GLA). (2020) (11)
Enhanced antitumoral effectiveness of idiotype vaccination induced by the administration of Flt3 ligand combined with interleukin 2 against a murine myeloma (2002) (11)
THE ROLE OF THE SPLEEN AFTER BONE MARROW TRANSPLANTATION FOR PRIMARY MYELOFIBROSIS (1992) (11)
Transplantation with peripheral blood stem cells from unrelated donors without serious graft-versus-host disease. (1995) (11)
Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B‐cell lymphoma: mature results of a phase II multicentre study (2015) (11)
Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group (2016) (11)
Therapy‐associated genetic aberrations in patients treated for non‐Hodgkin lymphoma (2008) (11)
Treatment of refractory Hodgkin's disease with high‐dose cytosine arabinoside and mitoxantrone in combination. Results of a clinical phase II study of the German Hodgkin study group (1990) (11)
PBPC grafts from healthy donors: analysis of CD34+ and CD3+ subpopulations. (1996) (11)
Dose Escalated CHOP + Etoposide Followed by Repetitive Autologous Stem Cell Transplantation (MegaCHOEP) with or without Rituximab for Primary Treatment of Aggressive NHL. (2005) (10)
Philadelphia chromosome (Ph) positive chronic myelocytic leukemia (CML): frequency of additional findings. (1985) (10)
Diffuse Large B-Cell Lymphoma (DLBCL) Patients Failing Second-Line R-DHAP Or R-ICE Chemotherapy Included In The Coral Study (2013) (10)
Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial. (2021) (10)
High expression of the immature laminin receptor protein correlates with mutated IGVH status and predicts a favorable prognosis in chronic lymphocytic leukemia. (2011) (10)
Transfer of idiotypic protein primed allogeneic marrow grafts elicits potent graft-versus-myeloma effects in mice (2001) (10)
Lymphohaematopoietic chimaerism after bone marrow transplantation for chronic myeloid leukaemia: results of simultaneous cytogenetic analyses on T‐cell colonies, myeloid, and erythroid progenitor cells (1991) (10)
German High-Grade Non-Hodgkin Lymphoma Study Group analysis of patients with T-cell lymphoma treated in studies of the Treatment and prognosis of mature T-cell and NK-cell lymphoma: an (2013) (10)
Dose-Dense Rituximab in Combination with Biweekly CHOP-14 for Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of a Phase-I/II and Pharmacokinetic Study of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). (2006) (10)
Superior antileukemic activity of murine peripheral blood progenitor cell (PBPC) grafts mobilized by G-CSF and stem cell factor (SCF) as compared to G-CSF alone. (1998) (9)
Validation of the ELN 2017 Classification for AML with Intermediate Risk Cytogenetics with or without NPM1 -Mutations and High or Low Ratio FLT3-ITD s (2017) (9)
Autologous Stem Cell Transplantation for Patients with Early Progression of Follicular Lymphoma- Retrospective Analysis of 2 Randomized Trials of the German Low Grade Lymphoma Study Group (GLSG) (2016) (9)
Patients with Lymphoplasmacytic Lymphoma Can Be Salvaged with Autologous Stem Cell Transplantation, Irrespectively of the Number of Previous Treatment Lines. Analysis of 146 Cases from the European Bone Marrow Transplant Registry (EBMT). (2004) (9)
HuMax-CD4 (Zanolimumab), a Fully Human Monoclonal Antibody: Early Results of an Ongoing Clinical Trial in CD4+ Peripheral T-Cell Lymphoma of Non-Cutaneous Type. (2005) (9)
DURABLE BENEFIT OF RITUXIMAB MAINTENANCE POST‐AUTOGRAFT IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA: 12‐YEAR FOLLOW‐UP OF THE EBMT LYMPHOMA WORKING PARTY LYM1 TRIAL (2017) (9)
Haploidentical stem cell transplantation for patients with lymphoma: a position statement from the Lymphoma Working Party-European Society for Blood and Marrow Transplantation (2019) (9)
Response: Intrathecal methotrexate and central nervous system events. (2009) (9)
Abrogation of graft-vs.-leukemia activity after depletion of CD3+ T cells in a murine model of MHC-matched peripheral blood progenitor cell transplantation (PBPCT). (1998) (9)
Autologous Stem Cell Transplantation after Myeloablative Therapy in First Remission May Be Beneficial in Patients with Advanced Stage Follicular Lymphoma after Front-Line Therapy with R-CHOP. An Analysis of Two Consecutive Studies of the German Low Grade Lymphoma Study Group (GLSG) (2008) (9)
Allogeneic Stem Cell Transplantation Can Overcome the Adverse Prognostic Impact of TP53 Mutation In Chronic Lymphocytic Leukemia (CLL): Results From the GCLLSG CLL3x Trial (2010) (9)
The role of allogeneic stem‐cell transplantation in Hodgkin's disease (2005) (9)
Independent Predictive Value of PET-CT Pre Transplant in Relapsed and Refractory Patients with CD20 Diffuse Large B-Cell Lymphoma (DLBCL) Included in the CORAL Study. (2009) (9)
Refractory or relapsed aggressive B-cell lymphoma failing (R)-CHOP: an analysis of patients treated on the RICOVER-60 trial (2017) (9)
Obesity negatively impacts outcome in elderly female patients with aggressive B‐cell lymphomas treated with R‐CHOP : results from prospective trials of the German high grade non‐Hodgkin's lymphoma trial group (2018) (9)
Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (2020) (8)
Long Term Outcome and Late Effects in Patients Transplanted with Filgrastim-Mobilized Blood or Bone Marrow Treated in a Randomized Trial. A Study from the EBMT Late Effects Working Party (2008) (8)
Unusual Biventricular Thrombus Formation in Acute Myeloid Leukemia and Factor V Leiden Mutation (2003) (8)
Allogeneic Bone Marrow Transplantation for Childhood Acute Lymphoblastic Leukemia in Second Remission After Intensive Primary and Relapse Therapy (2003) (8)
Rituximab in autologous stem cell transplantation for follicular lymphoma. (2001) (8)
Seroconversion for hepatitis C virus antibody in bone marrow recipients treated with immune globulin. (1991) (8)
Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics (2021) (8)
High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin's disease (1993) (8)
Impact of Autologous Stem Cell Transplantation and/or Rituximab on Outcome of Patients with Relapsed Follicular Lymphoma- Retrospective Analysis of 2 Randomized Trials of the German Low Grade Lymphoma Study Group (GLSG). (2008) (8)
Changes in patients population and characteristics of hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma: an analysis of the Lymphoma Working Party of the EBMT (2020) (8)
Doubling rituximab in high‐risk patients with aggressive B‐cell lymphoma ‐results of the DENSE‐R‐MegaCHOEP trial (2018) (8)
Allogeneic Stem Cell Transplantation Confers a Favorable Outcome in Patients with NPM1 Positive Acute Myeloid Leukemia: Results From a Donor Vs. No-Donor Analysis of 309 Patients Treated in the SAL AML-2003 Trial (2011) (8)
Central Nervous System Prophylaxis for Aggressive B-cell Lymphoma: Who, What, and When? (2016) (8)
Immunotherapeutic aspects of allogeneic peripheral progenitor cells. (1998) (7)
A Strong Immune Effect by Allogeneic Stem Cell Transplantation May Improve Survival in AML Patients with a High Ratio of the FLT3-ITD Mutation to the Wt-FLT3 Allele: Results from an Analysis of 257 Patients Treated in the SAL AML-2003 Trial (2011) (7)
Allogeneic transplantation of peripheral blood stem cells. (1999) (7)
Pegfilgrastim Supports Delivery of BEACOPP Chemotherapy Administered Every 14 Days. (2004) (7)
Prognostic Impact of Germinal Center (GC)/ Activated B-Cell (ABC) Classification Analysed by Immunochemistry, FISH Analysis and GEP, In Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The Bio-CORAL Study (2010) (7)
Optimization of Rituximab for Treatment of DLBCL in Young, High-Risk Patients-Results of the Dense-R-CHOEP Trial of the German High-Grade Lymphoma Study Group (2015) (7)
M-Phase Phosphoprotein 11 Is a Highly Immunogenic Tumor Antigen in Patients with Acute Myeloid Leukemia (2012) (7)
FIRST‐LINE THERAPY OF T‐CELL LYMPHOMA: ALLOGENEIC OR AUTOLOGOUS TRANSPLANTATION FOR CONSOLIDATION ‐ FINAL RESULTS OF THE AATT STUDY (2019) (7)
High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood (2001) (7)
Bi-weekly dosing preserves the efficacy of rituximab in elderly patients with poor-prognosis DLBCL: Results from the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study group (DSHNHL). (2006) (7)
Amplification of a Y‐chromosomal DNA sequence by the polymerase chain reaction for documentation of residual recipient cells in small samples from bone marrow, peripheral blood and cerebrospinal fluid after bone marrow transplantation (1993) (7)
Hepatitis B viremia in a patient with documented previous HBV immunity after autologous transplantation of highly purified PBSC (2000) (7)
Remission of juvenile chronic myeloid leukemia following graft failure of an unrelated marrow transplant and autologous recovery of marrow function promoted by GM-CSF and IL-3. (1991) (7)
Dose escalated CHOP + etoposide and repetitive autologous stem cell transplantation (MegaCHOEP) with and without rituximab for primary treatment of aggressive NHL (2005) (7)
The conditional survival analysis of relapsed DLBCL after autologous transplant: a subgroup analysis of LY.12 and CORAL. (2020) (7)
Reduced Intensity Allogeneic Stem Cell Transplantation for Mantle Cell Lymphoma Is Associated with Substantial Late Transplant Related Mortality and a Poor Outcome in Patients with Chemoresistant Disease. (2004) (7)
Differences Between CEBPA bZIP and TAD Mutations and Their Effect on Outcome-an Analysis in 4578 Patients with Acute Myeloid Leukemia (2016) (7)
Upfront Allogeneic Stem Cell Transplantation for Remission Induction in High-Risk Acute Myeloid Leukemia Patients within the Randomized Multi- Center Trial AML2003. (2008) (7)
Patients with Mature T-Cell Lymphoma Show High Relapse Rates after High Dose Therapy and Autologous Stem Cell Transplantation (2008) (7)
Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study (2016) (6)
The Search for Surrogate Endpoints in Trials in Diffuse Large B‐Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project (2017) (6)
Dose-escalated CHOP plus etoposide (Hi-CHOEP) is not superior to base-line CHOEP in young good-prognosis patients with aggressive lymphoma: Results of a randomized DSHNHL trial. (2006) (6)
Early Autologous Stem Cell Transplantation (SCT) in Genetically Poor-Risk Chronic Lymphocytic Leukemia Is Feasible and Effective: Results from a Prospective Multicenter Study (GCLLSG CLL3 Protocol). (2004) (6)
High-dose chemotherapy followed by allogeneic stem cell transplantation in high-risk relapsed and refractory aggressive non-Hodgkin lymphoma: Results of a prospective study of the German high-grade non-Hodgkin lymphoma study group. (2012) (6)
Precast commercial polyacrylamide gels for separation of DNA amplificates by temperature gradient gel electrophoresis: Application to clonality analysis of lymphomas (1996) (6)
Acute monocytic leukemia with translocation t(1;11) (p31;q23): simultaneous staining of chromosomes and cell surface antigens. (1990) (6)
Reduced-intensity conditioning and allogeneic stem cell transplantation in mantle cell lymphoma: an update from the Lymphoma Working Party of the EBMT (2006) (6)
Minimal Residual Disease (MRD) Kinetics after Autologous Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL) Correlate to IgH VH Mutational Status and Predict Post Transplant Outcome: Real Time ASO-IgH PCR Results of the GCLLSG CLL3 Protocol. (2004) (6)
Matched Unrelated Donor Stem Cell Transplantation for Relapsed or Refractory Mantle Cell Lymphoma. A Retrospective Analysis from the EBMT Lymphoma Working Party. (2006) (6)
Pegfilgrastim (6mg or 12mg) Mobilizes CD34+ Cells Similarly to Filgrastim (5mcg/kg/day) When Administered Following Chemotherapy in Patients with Non-Hodgkin’s Lymphoma. (2005) (6)
Repetitive high-dose therapy followed by autologous stem cell transplantation (megachoep) for primary treatment of aggressive Nhl: the impact of rituximab on outcome and toxicity (2006) (6)
Stem Cell Mobilization in Healthy Donors: Current Status (1999) (6)
Long-Term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 10-Year Follow-up of the Gcllsg CLL3X Trial (2016) (6)
Danazol in acquired amegakaryocytic thrombocytopenic purpura: A case report (1985) (6)
Relapsed/Refractory International Prognostic Index (R/R‐IPI): An international prognostic calculator for relapsed/refractory diffuse large B‐cell lymphoma (2021) (6)
CNS Disease In Younger Patients (<=60 years) with Aggressive Lymphoma Treated In Trials of the German High Grade Non Hodgkin Lymphoma Study Group (DSHNHL) and the MabThera International Trial (MInT) (2010) (6)
CHOP/CHOEP-14 followed by consolidation with alemtuzumab in untreated aggressive T-cell lymphomas (DSHNHL 2003-1): Feasibility and toxicity of a phase II trial of the German High Grade Non-Hodgkin's Lymphoma Group DSHNHL. (2006) (6)
Survival and Freedom from Progression in Autotransplant Lymphoma Patients is Independent of Stem Cell Source: Further Follow-up from the Original Randomised Study to Assess Engraftment (2002) (5)
Enhanced antileukemic activity of allogeneic peripheral blood progenitor cell transplants following donor treatment with the combination of granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF) in a murine transplantation model (2003) (5)
Reduced intensity allogeneic stem cell transplantation for Hodgkin's disease: An analysis from the European group for Blood and Marrow Transplantation. (2002) (5)
Rituximab Purging and Maintenance Improves Progression Free Survival but Not Overall Survival In Patients with Relapsed or Resistant Follicular Lymphoma Prior Receiving An Autologous Transplant (2010) (5)
Consensus conferences : guidelines on malignant lymphoma . part 2 : marginal zone lymphoma , mantle cell lymphoma , peripheral T-cell lymphoma (2013) (5)
Fractionated total body irradiation plus high-dose VP-16 prior to allogeneic bone marrow transplantation in children with poor risk acute leukaemias. (1989) (5)
Influence of G-CSF on NK cell recovery after autologous BMT. (1994) (5)
The Effects of Induction Chemotherapy and High-Dose Melphalan with Tandem Autologous Transplantation in Multiple Myeloma: The Prospective Randomized DSMM 2 Study. (2007) (5)
Acute myelomonocytic leukemia with involvement of eosinophils and inversion of chromosome 16 (1984) (5)
Mature T-cell lymphoma patients show high relapse rates after high dose therapy followed by autologous transplantation (2008) (5)
Images in cardiovascular medicine. Unusual biventricular thrombus formation in acute myeloid leukemia and factor V Leiden mutation. (2003) (5)
Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative forFLT3-ITD,NPM1- or biallelicCEBPA mutations. (2017) (5)
[Problems of intravenous urography in patients with plasmocytoma]. (1983) (5)
Induction Treatment In Elderly Patients with Acute Myeloid Leukemia (AML): Randomized Comparison of Intermediate-Dose Cytarabine Plus Mitoxantrone (IMA) Versus Standard-Dose Cytarabine Plus Daunorubicin (DA) In 492 AML Patients >60 Years – Results From the SAL 60plus Trial (2010) (5)
Haplotransplants Versus Other Alternative Donors for Allogeneic Stem Cell Transplantation in Non Hodgkin Lymphoma (NHL): A Retrospective Analysis of the EBMT Lymphoma Working Party (2014) (5)
First international symposium on allogeneic peripheral blood precursor cell transplants. (1996) (4)
Successful stimulation of autologous bone marrow recovery by GM-CSF and IL-3 after an unrelated donor BMT for juvenile CML complicated by graft failure. (1991) (4)
The role of allogeneic stem cell transplantation in T-cell lymphoma (2018) (4)
Immunoblastic morphology but not the immunohistochemical GCB/non-GCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL Running title: OUTCOME PREDICTION IN DLBCL (2010) (4)
Successful autologous stem cell transplantation in a severely immunocompromised patient with relapsed AIDS-related B-cell lymphoma. (2006) (4)
Durable benefit of rituximab maintenance post-autograft in patients with relapsed follicular lymphoma: 12-year follow-up of the EBMT lymphoma working party Lym1 trial (2021) (4)
2-weekly vs 3-weekly CHOP with and without Etoposide in Young Patients with Low-Risk Aggressive Non-Hodgkins Lymphoma Results of the Completed NHL-B-1 Trial of the DSHNHL (2002) (4)
Fourth interim analysis of the HD R2 study, a europeanmulticenter trial for patients with relapsed Hodgkin lymphoma (2007) (4)
Risk Stratification and Prognostic Factors in Elderly AML Patients – Updated Results of 909 Patients Entered Into the Prospective AML96 Trial. (2009) (4)
Age and Time to Progression Predict Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Who Progress Following Frontline Immunochemotherapy (IC) (2019) (4)
Allogeneic Stem Cell Transplantation with Intermediate Conditioning Is Effective in High Risk Relapse and Progressive Disease of Aggressive Non-Hodgkin-Lymphoma. (2009) (4)
Randomized Comparison of Intermediate-Dose Cytarabine Plus Mitoxantrone (IMA) Versus Standard-Dose Cytarabine Plus Daunorubicin (DA) for Induction Therapy in AML Patients >60 Years. Results from the SAL 60+ Trial (2015) (4)
Allogeneic Stem Cell Transplantation (Allo-SCT) in the Management of Advanced Waldenstrom’s Macroglobulinemia (WM). (2007) (4)
Treatment of primary CNS lymphoma. (2015) (4)
Transplant activities in Germany in 1998 – a survey facilitated by the National Registry for Hemopoietic Stem Cell Transplantation (2000) (3)
Response Adapted Assignment of the Number of Chemotherapy Cycles for the Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Is Not Justified: Results of the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). (2007) (3)
Developments and Quality Assurance in Stem Cell Transplantationfrom a German National Registry (2006) (3)
Outcome of Elderly Patients with DLBCL Failing R-CHOP: The Role of Rituximab and High Dose Therapy in Second Line Treatment. A Retrospective Analysis From the RICOVER 60 Trial. (2009) (3)
Zanolimumab, a fully human monoclonal antibody: preliminary results of an ongoing clinical trial in CD4+ peripheral T-cell lymphomas (PTCL) (2006) (3)
KIR2DS1-HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials. (2022) (3)
[Ultrahigh-dosage cytostatics--their possible use in acute leukemias?]. (2008) (3)
Anti-infective prophylaxis with aciclovir and cotrimoxazole to reduce the rate of infections and therapy-associated deaths in elderly patients with DLBCL undergoing R-CHOP immunochemotherapy. (2017) (3)
Matched unrelated donor (MUD) bone marrow transplantation for adults and children with non-Hodgkin's lymphoma and Hodgkin's lymphoma: preliminary analysis of 56 cases reported to EBMT lymphoma registry. (1999) (3)
CNS-Disease in Elderly Patients Treated with Modern Chemotherapy (CHOP-14) with or without Rituximab: An Analysis of CNS Events in the RICOVER-60 Trial of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL). (2007) (3)
The Clinical Impact of the Cell-of-Origin Classification and the MYC+/BCL2+ Double Expresser Status in DLBCL Treated within Prospective Clinical Trials of the Dshnhl (2016) (3)
Secondary Malignancies After Autologous Stem Cell Transplantation In Patients With Relapsed / Refractory Hodgkin´s Lymphoma. A Retrospective Analysis On Behalf Of The Lymphoma Working Party Of The European Society For Blood and Marrow Transplantation (EBMT) (2013) (3)
Can corporatization contribute to quality assurance and cost control in the German hospital sector? A pilot project for stem cell transplantation. (1999) (3)
The role of myeloablation for lymphoma. (2014) (3)
Prognostic Relevance of Dose-Density of DHAP-Reinduction Therapy in Relapsed HL: An Analysis of the German Hodgkin-Study Group (GHSG) (2012) (3)
The Impact of Disease Status at Transplant and Time to First Relapse on Outcome in Children and Adolescents with Hodgkin’s Lymphoma Undergoing Autologous Stem Cell Transplantation. (2004) (3)
Donor Lymphocyte Infusions for the Treatment of Relapsed Non-Hodgkin Lymphoma Following Allogeneic Stem Cell Transplantation: A LWP-EBMT Study (2018) (3)
Anti-infective prophylaxis with aciclovir and cotrimoxazole significantly reduces the rate of infections and therapy-associated deaths in elderly patients with DLBCL undergoing R-CHOP immunochemotherapy (2017) (3)
Early Autologous Stem Cell Transplantation (autoSCT) May Overcome the Adverse Impact of Del 11q- in Poor-Risk Chronic Lymphocytic Leukemia (CLL): Results From the GCLLSG CLL3 Trial. (2009) (3)
The Impact of Allogeneic Hematopoietic Stem Cell Transplantation in Children and Adolescents with Recurring Hodgkin’s Lymphoma: An EBMT Study on 151 Patients. (2007) (3)
Non-Hodgkin Lymphoma Study Group (DSHNHL) of patients treated in the RICOVER-60 trial of the German High-Grade modern chemotherapy (CHOP-14) with or without rituximab: an analysis CNS events in elderly patients with aggressive lymphoma treated with (2013) (3)
[Analysis of prognostic factors in plasmacytoma]. (1984) (3)
Excellent outcome of young adults with aggressive non-Hodgkin lymphomas treated with CHOP-like regimens (2014) (3)
Plasmapheresis in paraproteinemia (1985) (3)
Randomized trial comparing filgrastim-mobilized peripheral blood progenitor cell transplantation with autologous bone marrow transplantation in lymphoma patients (1997) (2)
Event-Free Survival As a Surrogate for Overall Survival in Relapsed DLBCL after Autologous Transplant: A Subgroup Analysis of LY.12 and Coral (2019) (2)
[Autologous bone marrow transplantation in Hodgkin's disease]. (2008) (2)
[Current status of chemotherapy for Hodgkin's disease]. (1981) (2)
Standard of Care in First-Line Therapy of DLBCL (2018) (2)
Modified BEAM with triple autologous stem cell transplantation for patients with relapsed aggressive non-Hodgkin lymphoma (2016) (2)
Identification of HLA-A*0201-presented T-cell epitopes derived from the tumor-associated antigen M-phase phosphoprotein II in patients with acute myeloid leukemia (2010) (2)
Autologous or allogeneic transplantation in B- and T-cell lymphomas. (2012) (2)
Systemic ALK-Positive Anaplastic Large-Cell Lymphoma (ALCL): Final Analysis of an International, Individual Patient Data Study of 263 Adults (2017) (2)
CNS relapse in DLBCL patients below 60 years treated with R-ACVBP, R-CHOEP, or R-CHOP: A joint analysis of LYSA and GLA/DSHNHL. (2021) (2)
Evaluation of Progression-Free Survival (PFS) As a Surrogate Endpoint for Overall Survival (OS) in First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): Findings from the Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 7507 Patients (2016) (2)
The role of autologous stem cell transplantation (ASCT) in aggressive B-cell lymphomas: real-world data from a retrospective single-center analysis (2021) (2)
Correction: High-risk additional chromosomal abnormalities at low blast counts herald death by CML (2020) (2)
Two Cycles of Risk-Adapted Consolidation Leads to a Favorable Long-Term Prognosis in Patients with Acute Promyelocytic Leukemia After Standard AIDA Induction: Results From 141 Patients Treated in the SAL-AIDA-2000 Trial (2011) (2)
The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial diffuse large B-cell lymphoma. (2013) (2)
No Benefit of Combining Additional Compounds with Standard High Dose Cytarabine Consolidation: Results of the Prospective Randomized AML2003 Study (2011) (2)
Role of radiotherapy for elderly DLBCL patients in the rituximab (R) era: Final results of the RICOVER-60-no-rx study of the DSHNHL. (2012) (2)
Impact of telomere length on the outcome of allogeneic stem cell transplantation for poor‐risk chronic lymphocytic leukaemia: results from the GCLLSG CLL3X trial (2017) (2)
HLA-identical allogeneic stem cell transplantation for patients with primary cutaneous T-cell lymphoma: a retrospective analysis of the Lymphoma Working Party of the European Blood and Marrow Transplantation Group (2009) (2)
Long-term follow-up of high-dose treatment (HDT) with autologous haematopoietic progenitor cell support in 702 patients (pts.) with follicular lymphoma (FL). An EBMT registry study. (2006) (2)
Allogeneic Stem Cell Transplantation Results in a Low Relapse Rate in Patients with Peripheral T-Cell Lymphoma. (2008) (2)
Allogeneic Hematopoietic Cell Transplantation For Patients With Mycosis Fungoides and Sezary Syndrome: The Experience Of The EBMT Lymphoma Working Party With An Extended Five-Year Follow Up (2013) (2)
Selective antilymphocyte sera (SAL) in bone marrow transplantation. I. In vitro characterization of antihuman SAL and the development of absorption procedures using cultured cell lines. (1985) (2)
Final Analysis of Phase II Study of CHOP/CHOEP-14 Followed by Consolidation with Alemtuzumab in Untreated Aggressive T-Cell Lymphomas (DSHNHL 2003–1). (2007) (2)
6. Report on Workshop: EBMT Workshop “High dose therapy in aggressive NHL” (2001) (2)
[Elevated cyclosporin A level during simultaneous therapy with danazol]. (1986) (2)
High-Dose Therapy and Autologous Stem Cell Transplantation for Extra-Nodal NK/T Lymphoma in Western Patients; A Study From the European Group for Blood and Marrow Transplantation (EBMT). (2012) (2)
Clinical Post-SARS-CoV-2 Infection Scenarios in Vaccinated and Non-Vaccinated Cancer Patients in Three German Cancer Centers: A Retrospective Analysis (2022) (2)
The impact of high-intensity conditioning prior to allogeneic stem cell transplantation in patients with chemorefractory or relapsed T-cell lymphoma. (2011) (2)
Two cases of graft-versus-host disease following transfusion of nonirradiated blood products (1982) (2)
MRD Kinetics Can Predict the Time to Relapse after Autologous Stem Cell Transplantation (SCT) in Chronic Lymphocytic Leukemia (CLL). (2005) (2)
[The practice of chemotherapy with the DeVita protocol]. (2008) (2)
Repetitive High-Dose Therapy with Dose Escalated CHOP + Etoposide Followed by Autologous Stem Cell Transplantation (Mega-CHOEP) in Younger Patients with Primary Diagnosis of Aggressive NHL and Elevated LDH at Diagnosis: Final Analysis. (2004) (2)
ANTI‐INFECTIVE PROPHYLAXIS WITH ACICLOVIR AND COTRIMOXAZOLE SIGNIFICANTLY REDUCES THE RATE OF INFECTIONS AND THERAPY‐ASSOCIATED DEATHS IN ELDERLY PATIENTS WITH DLBCL UNDERGOING R‐CHOP IMMUNOCHEMOTHERAPY (2017) (1)
Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Relapsing after Autologous Stem Cell Transplantation (ASCT): An Analysis of Patients Included in the Coral Study (2015) (1)
CD48 monoclonal antibody K31 for bone marrow transplantation. (1992) (1)
Outcome of elderly DLBCL patients with 6xCHOP-14 and 8 rituximab (R) applications given over an extended period (SMARTE-R-CHOP-14 trial of the DSHNHL). (2012) (1)
Allogeneic Stem Cell Transplantation with Dose-Reduced Conditioning in Relapsed Follicular and Mantle Cell Lymphoma - A Prospective Phase II Trial of the German Low Grade Lymphoma Study Group (GLSG). (2007) (1)
Evidence for rituximab (R) underdosing in subpopulations of elderly patients with DLBC: Results of the RICOVER-60 study of the DSHNHL. (2012) (1)
Rituximab Overcomes Sex as a Strong Adverse Prognostic Factor for Treatment Outcome in Patients with Follicular Lymphoma: Analysis of Patients Treated with Rituximab/CHOP or CHOP in Randomized Trials of the German Low Grade Lymphoma Study Group (GLSG). (2009) (1)
Severe Donor Events after Allogeneic Hematopoietic Stem Cell Donation. (2007) (1)
Nilotinib In Combination With Chemotherapy For First-Line Treatment In Elderly Patients With Philadelphia-Positive All: Results Of The European Working Group For Adult All(Ewall-Ph-02) (2015) (1)
Hla-identical Allogeneic Stem Cell Transplantation (allosct) for Patients With Primary Cutaneous T-cell Lymphoma (ctcl): a Retrospective Analysis of the Lymphoma Working Party of the European Blood and Marrow Transplantation Group (ebmt-lwp) (2009) (1)
[Therapy of highly malignant non-Hodgkin lymphoma with high-dose chemotherapy and stem cell transplantation]. (1998) (1)
Diffuse Large B-Cell Lymphoma (2018) (1)
Identification of a miRNA based model to detect prognostic subgroups in patients with aggressive B-cell lymphoma (2020) (1)
Mature T-/NK-cell lymphomas: Prognostic factors and treatment outcome of patients treated on studies of the German High-Grade Lymphoma Study Group (DSHNHL). (2009) (1)
Allogeneic Peripheral Blood Stem Cell vs. Bone Marrow Transplantation for Patients with Chronic Myeloid Leukemia: Results of an Individual Patient Data Meta-Analysis. (2004) (1)
Allogeneic transplantation of blood stem cells: Coming of age? (2001) (1)
Efficacy of COVID-19 Booster Vaccines in Patients with Hematologic Malignancies: Experiences in a Real-World Scenario (2022) (1)
CD48 monoclonal antibody K31 for bone marrow transplantation: T-depleting capacity and influence on hematopoietic progenitors. (1993) (1)
[Juvenile chronic leukemia and chronic myelomonocytic leukemia. Experiences with bone marrow transplantation in childhood in 5 cases]. (1992) (1)
General Condition and Early Complications Have in Addition to Disease- Specific Factors a Significant Impact on Outcome - Prognostic Factors Revisited in 1657 Adult ALL Patients (15–55 years). (2008) (1)
REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION FOR MANTLE CELL LYMPHOMA: THE EBMT EXPERIENCE (2011) (1)
Long-Term Outcome of Allogeneic Stem Cell Transplantation (allo-SCT) in Patients with Waldenstrom Macroglobulinemia (WM)-a Retrospective Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT) (2016) (1)
[10 years of DeVita protocol]. (2008) (1)
Primr kutanes Gamma/Delta‐TZell‐Lymphom (2009) (1)
Relevance of target cell-induced apoptosis as mechanism of resistance against natural killer cells (2009) (1)
Conventional Immunochemotherapy (R-CHOEP) Vs High-Dose Immunochemotherapy (R-MegaCHOEP) in Younger Patients with High-Risk Aggressive B-Cell Lymphoma: 10-Year Long-Term Follow-up of a German Lymphoma Alliance (GLA) Study (2019) (1)
Bone marrow transplantation in childhood leukemia in West Germany. (1987) (1)
Humoral Immune Responses against the Immature Laminin Receptor Show Prognostic Significance in Patients with Multiple Myeloma. (2008) (1)
SF3B1 , NOTCH1 and TP53 Mutations Do Not Affect the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 6-Year Follow-up of the Gcllsg CLL3X Trial (2012) (1)
Minimum tolerable interval of 90yttrium ibritumomab-tiuxetan to autologous stem cell transplantation after high-dose chemotherapy with carmustin, etoposide, cytarabine, and melphalan for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. (2012) (1)
Treatment of Myeloid and Lymphoid Malignancies with Highly Purified Alloreactive CD56+CD3− NK-Cells and Haploidentical Stem Cell Transplantation: Promising Results of a Phase I Study. (2005) (1)
The Prognostic Impact Of Gene Rearrangements and Protein Expression Of MYC, BCL2 and BCL6 In Young High-Risk Patients With DLBCL (2013) (1)
[Virus etiology of Hodgkin's disease]. (2008) (1)
Anti-CD25 antibody-drug conjugates: improving the delivery of death to lymphoma cells? (2021) (1)
Combination of Lenalidomide and R-DHAP for Treatment of Relapsed and Refractory Aggressive B-NHL (2014) (1)
Allogeneic stem cell transplantation improves survival inpatients with AML characterized by a high allelic ratio ofmutant FLT3-ITD (2016) (1)
Rituximab Improves the Outcome of Upfront Autologous Stem Cell Transplantation in Mantle Cell Lymphoma: A Comparison of Different Strategies. (2007) (1)
Splenectomy for treatment of immune thrombocytopenic purpura (2005) (1)
High‐dose cytostatic agents in allogeneic bone marrow transplantation: comparison of the engraftment promoting potential (1991) (1)
Acute eosinophilic leukemia: characterization by cytochemistry, chromosomal analysis, and in vitro colony formation (1985) (1)
HLA-Identical Allogeneic Stem Cell Transplantation (alloSCT) for Patients with Primary Cutaneous T-Cell Lymphoma (CTCL): A Retrospective Analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (EBMT-LWP). (2008) (1)
Secondary Erythrocytosis Produced by the Tyrosine Kinase Inhibitors Sunitinib and Sorafenib (2008) (1)
The Role of Autologous Stem Cell Transplantation (ASCT) in Patients with Advanced Waldenström’s Macroglobulinemia. (2007) (1)
Azacitidine Followed By Intensive Induction/Consolidation Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML): Results from the Randomized AML-AZA Trial of the Study Alliance Leukemias (SAL) (2014) (1)
Favorable Influence of Pretransplant Rituximab but Not of High-Dose Ara-C in Upfront Autologous Stem Cell Transplantation (SCT) for Mantle Cell Lymphoma (MCL). (2005) (1)
Evaluation of Clinical Judgement at Initiation of AML-Therapy in Elderly Patients - A Prospective Randomized Trial. (2007) (1)
Peripheral blood progenitor cell but not bone marrow grafts are affected by previous Dexa-BEAM chemotherapy (1994) (1)
Early Dose Intensity Is Critical in Patients with Aggressive Lymphoma: A Randomized study Comparing Identical Doses of Cyclophosphamide, Adriamycin, Vincristine, Etoposide, and Prednisolone given as 4 or 6 cycles followed by Repetitive Transplantation of Stem Cells (Mega-CHOEP). (2004) (1)
Obesity Is a Prognostic Factor in Elderly Female Patients with Aggressive B-Cell Lymphomas Treated with R- CHOP (2015) (1)
[Therapy of recurrent high-grade non-Hodgkin's lymphoma]. (1997) (1)
[Chronic myelocytic leukemia: indication for bone marrow transplantation]. (2008) (1)
Risk Stratification Using a New Prognostic Model for Patients with Secondary Acute Myeloid Leukemia - Results of the DSIL-AML96 Trial. (2009) (1)
Allogeneic Stem Cell Transplantation Improves Survival in Patients with FLT3-ITD-Negative and NPM1-Wild Type Intermediate Risk (ELN) Acute Myeloid Leukemia (2016) (1)
DONOR LYMPHOCYTE INFUSIONS INDUCE DURABLE RESPONSES IN PATIENTS WITH FOLLICULAR, MANTLE AND T CELL LYMPHOMAS RELAPSING AFTER AN ALLOSCT. AN EBMT‐LWP STUDY (2019) (1)
Age-dependent analysis of toxicity, mortality, and implementation of an anti-infective prophylaxis in 1171 elderly patients (pts) with aggressive B-cell lymphoma (aNHL): Data from consecutive phase II and III trials of the DSHNHL. (2016) (1)
Rituximab during Pregnancy: Serum Levels, B Cell Counts and Immunoglobulin Levels in Mother and Child. (2005) (0)
[Intrathoracic involvement in Hodgkin's disease. Diagnosis--therapy--prognosis]. (1986) (0)
Allogeneicstem cell transplantation for patients with Waldenstrms Macroglobulinaemia. Analysis of 106 cases from the European bone marrow registry (EBMT) (2007) (0)
[Results of radiotherapy in case of Hodgkin's disease after primary failure of chemotherapy and recurrence after chemotherapy ]. (1982) (0)
Wilsede-Schule für Onkologie und Hämatologie – Wilsede School for Oncology and Hematology (1995) (0)
MINIMUM TOLERABLE INTERVAL OF (90)YTTRIUM IBRITUMOMAB-TIUXETAN TO AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER HIGH-DOSE CHEMOTHERAPY WITH CARMUSTIN, ETOPOSIDE, CYTARABINE, MELPHALAN IS 10 DAYS. FIRST RESULTS FROM DSHNHL ESC Z-BEAM TRIAL FOR RELAPSED OR REFRACTORY AGGRESSIVE B-NHL (2011) (0)
The Impact of Rituximab and Radiotherapy On Treatment Outcome of Patients with DLBCL and Skeletal Involvement (2012) (0)
[Current diagnostic and therapeutic standards in aggressive B-cell lymphomas]. (2020) (0)
FIRST‐LINE THERAPY OF ELDERLY PATIENTS WITH DLBCL‐A COMPARISON OF STUDY PATIENTS TREATED WITH R‐CHOP ON THE RICOVER‐60 TRIAL AND PATIENTS TREATED WITH R‐CYCLOPHOSPHAMIDE, EPIRUBICIN, VINDESINE, PREDNISONE (R‐EpiVDSP) AT PEKING UNIVERSITY (2019) (0)
[Results of treatment with ABVD in C-MOPP-resistant Hodgkin's disease (author's transl)]. (1981) (0)
Cellular composition, antileukemic activity and hematopoietic potential of peripheral blood progenitor cell (PBPC) grafts mobilized by G-CSF and SCF (1997) (0)
Differential impact of sex in young and elderly patients with DLBC: Correlation with rituximab (R) pharmacokinetics. (2013) (0)
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PERIPHERAL T‐CELL LYMPHOMA: COMPARABLE OUTCOMES OF HAPLO‐IDENTICAL VS. MATCHED DONORS. A CIBMTR & EBMT ANALYSIS (2021) (0)
HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH LYMPHOMATOID GRANULOMATOSIS (2011) (0)
Allogeneic transplantation for children and adolescents with Hodgkin lymphoma. (2009) (0)
Unrelated Hematopoietic Blood Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia (AML) in First Remission. (2006) (0)
aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL for the treatment of young patients with good-prognosis (normal LDH) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide (2008) (0)
Kongressbericht – Congress Report (1995) (0)
Tbi using compensators: 16 years of experience in patients with b cell malignancies (2001) (0)
Allogene Knochenmarktransplantation bei akuten Leukämien (1989) (0)
Late Events in Patients with Relapsed or Refractory Hodgkin’s Lymphoma Treated with an Autologous Stem Cell Transplantation. (2007) (0)
5.8 Fludarabine-Cyclophosphamide-Rituximab vs Autologous Stem Cell Transplantation as First-Line Treatment for CLL: A Comparison of 2 Prospective Studies of the GCLLSG (2011) (0)
Aktuelle Standards in der Diagnostik und Therapie aggressiver B-Zell-Lymphome (2020) (0)
of the NHL-B2 trial of the DSHNHL the Treatment of Elderly Patients with Aggressive Lymphomas: Results 2-weekly or 3-weekly CHOP Chemotherapy with or without Etoposide for (2013) (0)
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (2020) (0)
Alkylator-Based Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) in Lymphoma: A Registry Study Comparing Thiotepa-, Busulfan-, Melphalan- and Treosulfan-Containing Regimens On Behalf of the EBMT Lymphoma Working Party (2012) (0)
[Allogeneic bone marrow transplantation after fractionated whole body irradiation. Results at the Kiel transplantation center]. (1985) (0)
Early Allogeneic Hematopoietic Cell Transplantation in Patients with High Risk AML - Final Results From the Randomized AML 2003 Trial (2012) (0)
aggressive lymphoma 182 BENEFIT OF ANTI-VIRAL AND PNEUMOCYSTIS CARINII PROPHYLAXIS IN PATIENTS TREATED WITH R-CHOP (2008) (0)
Proceedings of the First International Symposium on Allogeneic Peripheral Blood Progenitor Cell Transplantation : an EBMT Symposium : 26-28 October 1995, Geneva, Switzerland (1996) (0)
Brief an die Herausgeber · Letter to the Editors (2009) (0)
Reply to C. Fozza. (2013) (0)
[Clinical course of acute leukemia]. (1983) (0)
Reduction of Chemotherapy in Aggressive Non-Hodgkin's Lymphoma with Favorable Prognosis (2019) (0)
Early Versus Late Allogeneic Hematopoietic Cell Transplantation in Patients with AML - Results From the Randomized AML 2003 Trial (2013) (0)
Aggressive lymphoma (2011) (0)
Salvage Therapy of Adult ALL (1996) (0)
Enrichment of G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation by negative selection. (1994) (0)
PROSPECTIVE MULTICENTER REGISTRY FOR SECONDARY CNS INVOLVEMENT IN MALIGNANT LYMPHOMA: AN UPDATE WITH DATA FROM 181 PATIENTS (2019) (0)
[Clinical aspects of bone marrow transplantation]. (1986) (0)
Application of a microseparation technique allowing for extensive marker studies on small bone marrow specimens. (1987) (0)
Acute Erythroleukemia Morphology Does Not Confer an Unfavourable Prognosis in Itself. Results of a Subgroup Analysis of the Prospective Randomized AML96-, AML2003 and AML60+ Studies of the Study Alliance Leukemia (SAL) (2012) (0)
Humoral Immune Responses against the Immature Laminin Receptor Protein Show Prognostic Significance in Patients with Chronic Lymphocytic Leukemia 1 , 2 (2008) (0)
INTERNATIONAL SYMPOSIUM ON ALLOGENEIC BLOOD AND CORD BLOOD TRANSPLANTATION (1998) (0)
THE CLINICAL COURSE OF DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) OVER TIME: A MULTISTATE SURVIVAL ANALYSIS USING META‐DATA FROM 13 FIRST‐LINE RANDOMIZED TRIALS (2019) (0)
[Substitution with immunoglobulins in leukemia]. (1982) (0)
CURRENT THERAPY OF SECONDARY CNS INVOLVEMENT IN MALIGNANT LYMPHOMA: DATA FROM A MULTICENTER PROSPECTIVE INTERNATIONAL REGISTRY (2017) (0)
Allogeneic Hematopoietic Stem Cell Transplantation Achieves Long-Term Survival in Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party (2022) (0)
COMPARISON OF CLINICAL SCORING SYSTEMS IN AGGRESSIVE B‐CELL LYMPHOMAS (BCL): AN INDIVIDUAL PATIENT‐LEVEL ANALYSIS ACROSS INTERNATIONAL TRIAL (2019) (0)
A Study on the Prognosis of Patients Relapsing after Autologous Stem Cell Transplantation (auto-SCT) for Follicular Lymphoma (FL): The Impact of Remission Duration. (2006) (0)
Very early detection of donor cells after BMT in the blood, the oral cavity, and urinary tract by PCR (1994) (0)
Survivin-RNA-Transfected Dendritic Cells Hematological Malignancies Using and Human Individuals Against Generation of Cytotoxic Responses in Mice (2003) (0)
Interferon-α in the Treatment of CML: Comparison of Busulfan versus Hydroxyurea versus Interferon-α (1994) (0)
PROGNOSTIC FACTORS AND IMPACT OF ETOPOSIDE IN ADULTS WITH SYSTEMIC ALK‐POSITIVE ANAPLASTIC LARGE‐CELL LYMPHOMA: A POOLED ANALYSIS OF SIX STUDIES (2017) (0)
The role of thrombopoetin in growing hematopoietic stem cells. (2005) (0)
Rituximab and Bendamustine for First-Line Treatment of Frail or Elderly Patients with Aggressive B-Cell Lymphoma: Final Results of the Prospective Phase-II Brenda Trial of GLA (German Lymphoma Alliance) (2019) (0)
[IgD plasmacytoma]. (1984) (0)
Prognostic factors in COPP-treated patients with Hodgkin's disease (1982) (0)
Induction of Graft-versus-Leukemia-Activity after Peripheral Blood Progenitor Cell Transplantation (PBPCT) (1998) (0)
Comprehensive Risk Factor Analysis in 939 Adults with Acute Myeloid Leukemia Receiving Risk Stratified Post-Remission Therapy: Results of the Prospective Randomized AML96 Trial of the German Study Initiative Leukemia (DSIL). (2007) (0)
Proceedings of a Symposium on Immunology of Bone Marrow Transplantation : Current Controversies, June 3-5, 1993, Kiel/Germany (1993) (0)
A new approach to safeguard high standards and cost containment of stem cell transplantation in Germany. (1999) (0)
[Primary treatment of hairy cell leukemia with low-dose human recombinant interferon-alpha-2c (Hr-IFn alpha 2c) in comparison with therapy following splenectomy. Interferon (IFn-alpha 2c) in HCL before or after splenectomy]. (1987) (0)
Telomere Lenght and Outcome of Allogeneic Stem Cell Transplantation for Poor Risk Chronic Lymphocytic Leukemia: Results from the GCLLSG CLL3X Trial (2014) (0)
TP53 Mutation Is an Independent Predictor of Poor Survival in Untreated Patients with CD20+ Aggressive B-Cell Lymphoma: Analysis within the Ricover-60 Trial (2012) (0)
results of the German CLL Study Group CLL3X trial poor-risk chronic lymphocytic leukemia: long-term clinical and MRD Allogeneic stem cell transplantation provides durable disease control in (2011) (0)
Peripheral Blood Progenitor Grafts Obtained from Healthy Donors (1997) (0)
High-dose chemotherapy in lymphoma (1999) (0)
CART Therapy or Allogeneic Stem Cell Transplantation in ≥ Third Line Treatment of Large B Cell Lymphoma (LBCL) (2022) (0)
Minimum Tolerable Interval of Radioimmunotherapy and Autologous Stem Cell Transplantation after High-Dose Chemotherapy for Relapsed or Refractory Aggressive B Cell Non-Hodgkin-Lymphoma Provides Excellent Disease Control (2014) (0)
First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA Trial (2022) (0)
Patients with Hematological Malignancies Antigen-Immature Laminin Receptor Protein Cell Epitopes Derived from the Oncofetal Identification of HLA-A * 0201-Presented T (2006) (0)
[Fractionated homogeneous whole body irradiation prior to bone marrow transplantation]. (1985) (0)
Elimination of minimal residual disease in chronic lymphocytic leukemia using allogeneic stem cell transplantation (2009) (0)
INTENSIVE IMMUNOCHEMOTHERAPY (R‐CHOEP) VS HIGH‐DOSE IMMUNOCHEMOTHERAPY (R‐MegaCHOEP) IN YOUNG PATIENTS WITH AGGRESSIVE B‐CELL LYMPHOMA: A 10‐YEAR LONG‐TERM FOLLOW‐UP (2019) (0)
shouldbereplaced.Itshouldbeusedfurtherontoallocatepatientsto riskgroupsandtoreportclinicaltrialsinlymphomasasthereference. (2011) (0)
Hodgkin's disease. (1984) (0)
[Results of high-dose cytarabine therapy. A review]. (1985) (0)
Nodale aggressive Non-Hodgkin-Lymphome (2006) (0)
Role of Allogeneic Stem Cell Transplantation in Lymphoplasmacytic Lymphoma. Analysis of 61 Cases from the European Bone Marrow Registry (EBMT). (2004) (0)
[Historical survey on the development of bone marrow transplantation]. (1989) (0)
PROSPECTIVE MULTICENTER STUDY FOR TREATMENT OF CHRONIC MYELOCYTIC-LEUKEMIA - COMPARISON OF BUSULFAN, HYDROCYUREA AND INTERFERON ALPHA (UPDATE APRIL, 1990) (1991) (0)
Cytotoxic drugs, collection of stem cells and hematologic recovery after autologous transplantation. (2005) (0)
Intrathecal methotrexate and central nervous system events (2009) (0)
malignancies antigen-immature laminin receptor for the treatment of hematologic Induction of cytotoxic T-cell responses against the oncofetal (2013) (0)
Mitoxantrone in combination with high dose cytosine arabinoside in therapy refractory malignant lymphomas (1988) (0)
Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/ DSHNHL analysis. (2023) (0)
Does hematopoietic stem cell transplantation improve patient outcome in juvenile myelomonocytic leukemia? (2005) (0)
Patterns of relapse and survival following high dose therapy and stem cell transplantation for non-Hodgkins lymphoma Results from the EBMT (1998) (0)
Axicabtagene Ciloleucel (Axi-Cel) versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma: ZUMA-7, A Phase 3, Randomized Study (2018) (0)
Allogeneic hematopoietic stem cell transplantation for therapy-related myeloid neoplasms following treatment of a lymphoid malignancy (2021) (0)
Clinicogenetic Risk Models in Patients Randomized to Receive Consolidative Autologous Stem-Cell Transplantation after Frontline R-CHOP for Advanced Follicular Lymphoma: An Analysis from the GLSG2000 Trial (2018) (0)
Peripheral Blood Stem Cells for Allogeneic Transplantation (2000) (0)
Aggressive craniofacial lymphoma in the pre-rituximab and rituximab era. (2011) (0)
R andomized S tudy t o E valuate t he U se o f H igh-Dose T herapy as P art o f P rimary T reatment f or " Aggressive" L ymphoma (2002) (0)
[Aggressive B-cell lymphoma: modern diagnostics and treatment]. (2014) (0)
Early relapses and failure to achieve complete remission are the main prognostic factors in CD20 diffuse large B-cell lymphoma (DLBCL) treated with R-ICE or R-DHAP followed by stem cell transplantation in the CORAL study : 218 (2008) (0)
Bone marrow transplantation in childhood leukaemia--experience and strategies in the Federal Republic of Germany. (1989) (0)
[Allogeneic bone marrow transplantation in chronic myeloid leukemia. The results of HLA-identical transplants in the Federal Republic of Germany]. (2008) (0)
Treatment of Chronic Myelogenous Leukaemia (1995) (0)
Intermediate Intensity Conditioning Followed by Allogeneic Peripheral Blood Stem Cell Transplantion for Treatment of High Risk Relapse of Aggressive Lymphoma. Interim Analysis of the DSHNHL R3 Study. (2007) (0)
Impact of vincristine dose reduction on outcomes of patients with aggressive B-cell lymphoma treated with (R) - CHOP. (2023) (0)
Blood and Bone Marrow Transplantation analysis from the Lymphoma Working Party of the European Group for an following reduced intensity allogeneic progenitor cell transplantation: Chemoresistant or aggressive lymphoma predicts for a poor outcome (2013) (0)
High-Dose Therapy and Autologous Stem-Cel l Transplantat ion Versus (2001) (0)
[Experiences with cytomegalovirus hyperimmunoglobulin after bone marrow transplantation]. (1985) (0)
DEXA-BEAM Salvage Chemotherapy and High-Dose Chemotherapy Followed by Autologous Bone Marrow Transplantation in Hodgkin’s Disease (1994) (0)
Elderly Patients with Acute Myeloid Leukemia Are Not All the Same: Results of the Prospective DSIL AML96 Trial. (2007) (0)
Reply to A. Korfel et al. (2016) (0)
European working group for adult ALL phase II trial of nilotinib in combination with chemotherapy for first-line treatment in elderly patients with de novo Philadelphiachromosome positive acute lymphoblastic leukemia (EWALL-PH-02) (2015) (0)
High-dose therapy and bone marrow transplantation in Hodgkin's disease (1993) (0)
[Possibilities and limits of bone marrow transplantation]. (1991) (0)
Trends in the Use of Hematopoietic Stem Cell Transplantation in the Management of Relapsed/Refractory Diffuse Large B Cell Lymphoma. a Retrospective Analysis of the Lymphoma Working Party of the EBMT (2022) (0)
Adding Etoposide to R-CHOP (R-CHOEP) Does Not Significantly Increase the Risk of Secondary Neoplasms in Patients with Aggressive B-Cell Lymphoma - Results from Randomized Phase 3 Trials of the German Lymphoma Alliance (GLA) (2020) (0)
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma (2020) (0)
transplantation lymphoma patients undergoing autologous peripheral blood stem cell (2011) (0)
Comment on Omuro et al , page 1403 Treatment of primary CNS lymphoma (2015) (0)
Cost-Effectiveness Analysis of Arsenic Trioxide in Combination with All-Trans Retinoic Acid in Acute Promyelocytic Leukemia with Pretreatment White Blood Counts <10G/L (2014) (0)
Upfront Autologous Stem Cell Transplantation (SCT) Ameliorates the Prognostic Disadvantage of an Intermediate/High-Risk FLIPI Score in Patients with Advanced Follicular Lymphoma (FL): Evidence from Two Independent Data Sets. (2005) (0)
Allogeneic Stem Cell Transplantation in Angioimmunoblastic T-Cell Lymphoma (AITL): A Retrospective Survey from the Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT). (2007) (0)
P14.10 Secondary CNS involvement in malignant lymphoma: Data from a multicenter prospective international registry. (2017) (0)
HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH LYMPHOMATOID GRANULOMATOSIS: A SURVEY OF THE LYMPHOMA WORKING PARTY OF THE EUROPEAN GROUP FOR BLOOD AND MARROW TRANSPLANTATION (EBMT) (2011) (0)
Efficacy of Rituximab Combined in Salvage- and High Dose-Therapy (HDT) for Patients with Relapsed NHL; Interim Analysis of a Multicenter Phase II Study. (2004) (0)
Humoral Immune Responses Against the Oncofetal-Antigen/Immature Laminin Receptor (OFA/iLR) in Patients with Chronic Lymphocytic Leukemia. (2006) (0)
High CD34+ cell yields and low rate of secondary MDS/AML using intensive mobilisation for early autologous stem cell transplantation in genetically poor-risk CLL: results from a prospective multicentre study (GCLLSG CLL3 protocol) (2005) (0)
Hematopoietic stem cell transplantation in patients with Lymphomatoid Granulomatosis (LG): A survey of the lymphoma working party of the European Group for Blood and Marrow Transplantation (EBMT) (2012) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Norbert Schmitz?

Norbert Schmitz is affiliated with the following schools:

Norbert Schmitz's Academic­Influence.com Rankings

Why Is Norbert Schmitz Influential?

Norbert Schmitz's Published Works

Published Works

What Schools Are Affiliated With Norbert Schmitz?

Norbert Schmitz's AcademicInfluence.com Rankings